Melanoma Epidemiology Forecast Report 2021-2029 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Melanoma – Epidemiology Forecast to 2029” report has been added to ResearchAndMarkets.com’s offering.

In the 8MM, epidemiologists forecast the diagnosed incident cases of melanoma to increase from 190,771 cases in 2019 to 222,458 cases in 2029, at an Annual Growth Rate (AGR) of 1.66%. The US will have the highest number of melanoma cases throughout the forecast period. The five-year diagnosed prevalent cases of melanoma in the 8MM are also expected to increase from 794,304 cases in 2019 to 947,373 cases in 2029 at an AGR of 1.93%.

Scope

• The Melanoma Epidemiology Report provides an overview of the risk factors and the global and historical trends for melanoma in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Australia, and Canada).
• The report includes a 10-year epidemiological forecast for the diagnosed incident cases of melanoma segmented by age (beginning at 18 years and ending at 85 years and older), sex, cancer stage at diagnosis (American Joint Commission on Cancer [AJCC] Stages I, II, III, and IV), and mutations (BRAF, BRAF V600E, BRAF V600K, BRAF Non-V600, NF1, BRAF/NF1, NRAS Q61, C-KIT, PD-L1 expression, tumor mutational burden [TMB], NTRK – mutations in tropomyocin receptor kinase [TRK]).
• The melanoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
• The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

• Develop business strategies by understanding the trends shaping and driving the global melanoma market.
• Quantify patient populations in the global melanoma market to improve product design, pricing, and launch plans.
• Organize sales and marketing efforts by identifying the age groups that present the best opportunities for melanoma therapeutics in each of the markets covered.
• Understand magnitude of melanoma by stage at diagnosis and mutations.

 

Key Topics Covered:

 

1 Table of Contents

1.1 List of Tables

1.2 List of Figures

 

2 Melanoma: Executive Summary

2.1 Catalyst

2.2 Related Reports

2.3 Upcoming Reports

 

3 Epidemiology

3.1 Disease Background

3.2 Risk Factors and Comorbidities

3.3 Global and Historical Trends

3.4 Forecast Methodology

3.4.1 Sources

3.4.2 Forecast Assumptions and Methods

3.4.3 Diagnosed Incident Cases of Melanoma

3.4.4 Diagnosed Incident Cases of Melanoma by Stage at Diagnosis

3.4.5 Mutations Among Diagnosed Incident Cases of Melanoma

3.4.6 Five-Year Diagnosed Prevalent Cases of Melanoma

3.5 Epidemiological Forecast for Melanoma, 2019-2029

3.5.1 Diagnosed Incident Cases of Melanoma

3.5.2 Sex-Specific Diagnosed Incident Cases of Melanoma

3.5.3 Age-Specific Diagnosed Incident Cases of Melanoma

3.5.4 Diagnosed Incident Cases of Melanoma by Stage at Diagnosis

3.5.5 Diagnosed Incident Cases of Melanoma by Mutations

3.5.6 Five-Year Diagnosed Prevalent Cases of Melanoma

3.6 Discussion

3.7 Epidemiological Forecast Insight

3.7.1 COVID-19 Impact

3.7.2 Limitations of the Analysis

3.7.3 Strengths of the Analysis

 

4 Appendix

 

For more information about this report visit https://www.researchandmarkets.com/r/xtjgyi.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]

For E.S.T. Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900